Attached files

file filename
EX-99.1 - ENZON PHARMACEUTICALS, INC.c63673_ex99-1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

___________

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported)

December 21, 2010

 

 

ENZON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware
0-12957
22-2372868
(State or other jurisdiction of incorporation)
(Commission File No.)
(IRS Identification No.)

 

 

685 Route 202/206, Bridgewater, New Jersey
08807
(Address of principal executive offices)
(Zip Code)

Registrant’s telephone number, including area code

(908) 541-8600

 

 

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

£   Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£   Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
£   Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 



 

 

Item 8.01 Other Events.

 

On December 21, 2010, Enzon Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the approval by the Company’s board of directors of a stock repurchase program for the repurchase of up to $200 million of the Company’s common stock. There can be no assurance as to the number of shares the Company will repurchase, if any.

 

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No. Description
   

99.1

Press Release Dated December 21, 2010

 

 

 



 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: December 21, 2010

 

 

 

By:

/s/ Andrew Rackear

 

   Andrew Rackear
    Vice President and General Counsel